Dysregulation of Hippo/YAP signaling has also been implicated in the therapy resistance like chemoresistance in non-small cell lung cancer and triple-negative breast cancer, suggesting that YAP/TAZ represent promising targets for combination therapeutic strategies (Chapeau et al., 2024). This evidence concerns the gene YAP1 and triple-negative breast carcinoma.